<DOC>
	<DOC>NCT03089450</DOC>
	<brief_summary>to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)</brief_summary>
	<brief_title>To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent</brief_title>
	<detailed_description>A Multicenter, subject-blinded, randomized study to evaluate safety and efficacy of CGBIO stent compared to Biomatrix Flex stent in patients undergoing drug-eluting stent procedure after coronary angiography</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina, Unstable</mesh_term>
	<mesh_term>Angina, Stable</mesh_term>
	<criteria>At least one lesion with a diameter stenosis &gt;50% suitable for coronary stent implantation in a vessel with a reference diameter ranging from 2.5 mm to 4.0 mm; Gr 1 â‰¤TIMI flow STsegment elevation MI Bifurcation lesion Chronic total occulusion Restenosis lesion Graft vessel lesion Patient has a history of bleeding diathesis or coagulopathy or patients in whom antiplatelet and/or anticoagulant therapy is contraindicated or in which patient will not be able to comply with dual antiplatelet therapy for at least 1 year Cardiogenic shock or hemodynamic compromise Existing impairment in liver and kidney.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>